

**Fads3 Antibody - N-terminal region**  
**Rabbit Polyclonal Antibody**  
**Catalog # AI13061****Specification**

---

**Fads3 Antibody - N-terminal region - Product Information**

Application	WB
Primary Accession	<a href="#">Q8K1P9</a>
Other Accession	<a href="#">NM_173137</a> , <a href="#">NP_775160</a>
Reactivity	Human, Mouse, Rat, Rabbit, Pig, Horse, Bovine, Guinea Pig, Dog
Predicted	Human, Mouse, Rat, Rabbit, Pig, Horse, Bovine, Guinea Pig, Dog
Host	Rabbit
Clonality	Polyclonal
Calculated MW	49kDa kDa

**Fads3 Antibody - N-terminal region - Additional Information****Gene ID** 286922**Other Names**

Fatty acid desaturase 3, 1.14.19.-, Fads3

**Format**

Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose.

**Reconstitution & Storage**

Add 50 ul of distilled water. Final anti-Fads3 antibody concentration is 1 mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at 20°C. Avoid repeat freeze-thaw cycles.

**Precautions**

Fads3 Antibody - N-terminal region is for research use only and not for use in diagnostic or therapeutic procedures.

**Fads3 Antibody - N-terminal region - Protein Information****Name** Fads3 {ECO:0000303|PubMed:19752397, ECO:0000303|PubMed:24070791}**Function**

Mammals have different sphingoid bases that differ in their length and/or pattern of desaturation and hydroxyl groups. The predominant sphingoid base that comprises mammalian ceramides is sphing-4-enine (sphingosine or SPH) which has a trans (E) desaturation at carbon 4. FADS3 is a desaturase that introduces a cis (Z) double bond between carbon 14 and carbon 15 of the sphingoid base (also known as long chain base, LCB), producing LCBs such as sphinga-4,14-dienine (SPD, d18:2(4E,14Z)) from SPH. Prefers SPH-containing ceramides (N-acylsphing-4-enines) as substrates. Capable of metabolizing also the SPH in its free form. SPD ceramides occur widely in mammalian tissues and cells. Due to their unusual structure containing

a cis double bond, SPD ceramides may have an opposite, negative role in lipid microdomain formation relative to conventional ceramides. Could be involved in the detoxification of 1-deoxy sphingolipids, by desaturating the cytotoxic 1-deoxysphinganine (1-deoxySA, m18:0), produced under pathological conditions, to 1-deoxysphingosine (1-deoxySO, m18:1). Although prefers SPH-containing ceramides (N-acylsphing-4-enines) as substrates, it also exhibits activity toward dihydrosphingosine-containing CERs (N-acylsphinganines) and produces 14Z-SPH-containing sphingolipids. Its desaturase mechanism involves an electron transfer facilitated by cytochrome b5 (By similarity). FADS3 also acts as a methyl-end fatty acyl coenzyme A (CoA) desaturase that introduces a cis double bond between the preexisting double bond and the terminal methyl group of the fatty acyl chain. Desaturates (11E)- octadecenoate (trans-vaccenoate, the predominant trans fatty acid in human milk) at carbon 13 to generate (11E,13Z)-octadecadienoate (also known as conjugated linoleic acid 11E,13Z-CLA) (PubMed:<a href="http://www.uniprot.org/citations/24070791" target="\_blank">24070791</a>, PubMed:<a href="http://www.uniprot.org/citations/30262139" target="\_blank">30262139</a>).

### Cellular Location

Endoplasmic reticulum membrane {ECO:0000250|UniProtKB:Q9Y5Q0}; Multi-pass membrane protein

### Tissue Location


Essentially expressed in liver and kidney and to a lesser extent in heart, adipose tissue, stomach and pancreas (at protein level) (PubMed:19752397). Higher expression in lactating mammary gland than in liver (PubMed:30262139)

## Fads3 Antibody - N-terminal region - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

## Fads3 Antibody - N-terminal region - Images



Host: Rabbit  
Target Name: Fads3  
Sample Tissue: Rat Kidney lysates

Antibody Dilution: 1.0µg/ml

**Fads3 Antibody - N-terminal region - References**

D'Andrea S.,et al.Submitted (JUL-2002) to the EMBL/GenBank/DDBJ databases.